Abstract #300676


The views expressed here are those of the individual authors
and not necessarily those of the ASA or its board, officers, or staff.


Back to main JSM 2002 Program page



JSM 2002 Abstract #300676
Activity Number: 213
Type: Contributed
Date/Time: Tuesday, August 13, 2002 : 10:30 AM to 12:20 PM
Sponsor: Biometrics Section*
Abstract - #300676
Title: Gene-drug Interactions in the Context of an Active-Control Trial
Author(s): Barry Davis*+ and Charles Ford and Eric Boerwinkle and Donna Arnett and John Eckfeldt and Henry Black
Affiliation(s): University of Texas School of Public Health and University of Texas School of Public Health and University of Texas School of Public Health and University of Minnesota and University of Minnesota and Rush Presbyterian-St. Luke's Medical Center
Address: 1200 Herman Pressler St., Houston, Texas, 77030, USA
Keywords: gene-drug interaction ; pharmacogenetics ; genotype ; active control ; clinical trial
Abstract:

Much has been written about methods for detecting gene-environment interaction in the framework of case-control studies, particularly with reference to the assumption of independence of genotype and exposure. In the context of a clinical trial, wherein one is examining gene-drug interactions with regard to outcomes, some of these techniques may be readily applied since these two factors are independent due to randomization. In the case of an active control trial, gene-drug interactions for genotype and exposure (new treatment vs. comparator) can be estimated. Also, the effect of the new treatment versus a putative placebo can be estimated using data from prior comparator vs. placebo-controlled trials. However, can one say anything about interactions of genotype and exposure (new treatment versus placebo)? Using independence of genotype and treatment and incorporating information on marginal effects (relative risks) of genotype and exposure from previous studies, such interaction can be estimated. Examples from the Genetics of Hypertension Associated Treatment, a large pharmacogenetics, ancillary study of a cardiovascular clinic trial, will be used to illustrate this method.


  • The address information is for the authors that have a + after their name.
  • Authors who are presenting talks have a * after their name.

Back to the full JSM 2002 program

JSM 2002

For information, contact meetings@amstat.org or phone (703) 684-1221.

If you have questions about the Continuing Education program, please contact the Education Department.

Revised March 2002